Clinical Trial Detail

NCT ID NCT02834013
Title Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Recruitment Recruiting
Gender both
Phase Phase 0
Variant Requirements No
Sponsors National Cancer Institute (NCI)
Indications

seminoma

salivary gland carcinoma

mucinous adenocarcinoma

paraganglioma

testicular non-seminomatous germ cell cancer

penile cancer

ovarian germ cell cancer

teratoma

gastric neuroendocrine neoplasm

placental choriocarcinoma

pseudomyxoma peritonei

scrotum squamous cell carcinoma

vaginal carcinoma

transitional cell carcinoma

pancreatic acinar cell adenocarcinoma

anal canal carcinoma

oropharynx cancer

thyroid gland carcinoma

fallopian tube adenocarcinoma

peripheral nerve sheath neoplasm

cervical adenocarcinoma

parathyroid carcinoma

ovary adenocarcinoma

bladder adenocarcinoma

placental site trophoblastic tumor

carcinosarcoma

trachea carcinoma

gastric squamous cell carcinoma

Advanced Solid Tumor

vaginal squamous tumor

adrenal cortex cancer

mucinous cystadenocarcinoma

ovarian squamous cell carcinoma

appendix adenocarcinoma

ovarian mucinous adenocarcinoma

testicular sex cord-stromal neoplasm

ureter squamous cell carcinoma

pulmonary neuroendocrine tumor

cervical squamous cell carcinoma

chondroma

serous cystadenocarcinoma

small intestine adenocarcinoma

oral cavity cancer

urethra squamous cell carcinoma

peritoneal serous adenocarcinoma

pituitary carcinoma

vulva adenocarcinoma

epithelioid sarcoma

spindle cell carcinoma

urethra adenocarcinoma

nasopharynx carcinoma

paranasal sinus cancer

endometrial adenocarcinoma

vulva squamous cell carcinoma

nasal cavity carcinoma

nasal cavity adenocarcinoma

gastrointestinal neuroendocrine tumor

lung carcinoma

intrahepatic cholangiocarcinoma

skin cancer

bronchiolo-alveolar adenocarcinoma

adrenal gland pheochromocytoma

extrahepatic bile duct carcinoma

ureter adenocarcinoma

giant cell tumor

esophageal carcinoma

cholangiocarcinoma

acinar cell carcinoma

seminal vesicle adenocarcinoma

Therapies

Ipilimumab + Nivolumab

Age Groups: adult senior

No variant requirements are available.